Yesterday on BSB we looked at the emerging landscape in western countries for cancer immunotherapies that target gamma delta T cells. Today we’re turning our attention to China.
There’s a lot of interest in cell therapies in China. Anyone who has seen one of Dr Carl June’s recent presentations will no doubt recall the slide he shows of how many CAR T trials are underway there.
What’s happening with gamma delta T cells in China, and in particular CAR γδ T cell therapies? Do the Chinese have a competitive advantage in this emerging field and what can we learn from some of the results that have been reported?
This is the fourth post in our mini-series on the potential of gamma delta T cells for cancer immunotherapy.